Format

Send to

Choose Destination

Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.

Author information

1
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas 75230, USA. juliorosenstock@dallasdiabetes.com

Abstract

PURPOSE OF REVIEW:

To review recent clinical trials of oral dipeptidyl peptidase-4 inhibitors and examine their role in managing type 2 diabetes mellitus.

RECENT FINDINGS:

Oral dipeptidyl peptidase-4 inhibitors improve islet function by increasing alpha-cell and beta-cell responsiveness to glucose, resulting in improved glucose-dependent insulin secretion and reduced inappropriate glucagon secretion. These agents appear to have physiologically based antihyperglycemic effects and may modify the progressive nature of type 2 diabetes mellitus. In clinical trials sitagliptin and vildagliptin have modest demonstrated effectiveness, with clinically meaningful reductions of glycated hemoglobin when used as monotherapy. They appear promising in combination or added to ongoing therapy with other antidiabetic drugs (e.g. metformin, thiazolidinediones, or insulin). Dipetidyl peptidase-4 inhibitors themselves are not associated with hypoglycemia or weight gain and appear to have a benign safety profile.

SUMMARY:

Oral dipeptidyl peptidase-4 inhibitors may prove valuable in the treatment of diabetes, given their effectiveness in reducing glycated hemoglobin with neutral weight effects and without the adverse events associated with other agents. Dipeptidyl peptidase-4 inhibitors appear to improve islet function and may modify the course of diabetes; this, however, must be confirmed with long-term controlled studies to demonstrate sustained glycemic control that translates into beta-cell preservation.

PMID:
17940427
DOI:
10.1097/MED.0b013e3280a02f65
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center